3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
2
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
47
Rituximab
31
fludarabine
29
Specimen Handling
13
Magnetic Resonance Spectroscopy
13
Doxorubicin
13
pirtobrutinib
11
Vincristine
11
Prednisone
11
fludarabine phosphate
10
Immunotherapy, Adoptive
10
Etoposide
10
Bendamustine Hydrochloride
10
obinutuzumab
8
Lenalidomide
8
Biopsy
8
venetoclax
7
polatuzumab vedotin
7
glofitamab
7
zanubrutinib
6
pembrolizumab
6
Dexamethasone
6
tafasitamab
5
ibrutinib
5
etoposide phosphate
5
acalabrutinib
5
Leukapheresis
5
tazemetostat
4
loncastuximab tesirine
4
Nivolumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
Inosine Monophosphate
×
1 year
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled